The global market for Myomectomy was estimated at US$779.3 Million in 2024 and is projected to reach US$1.2 Billion by 2030, growing at a CAGR of 8.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Myomectomy market.
Segments: Product Type (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer, Other Product Types); Procedure Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Myomectomy Market - Key Trends & Drivers Summarized
Why Is Myomectomy Becoming a Preferred Treatment for Uterine Fibroids?
Myomectomy, a surgical procedure for the removal of uterine fibroids while preserving the uterus, is increasingly being recognized as a preferred treatment option for women seeking fertility preservation. The rising prevalence of uterine fibroids, which affect millions of women globally, has led to increased awareness and diagnosis, boosting the demand for effective treatment solutions. Unlike hysterectomy, which involves the complete removal of the uterus, myomectomy offers women the ability to retain reproductive function, making it an attractive choice among younger patients. Technological advancements in minimally invasive surgical techniques, such as laparoscopic and robotic-assisted myomectomy, have further improved patient outcomes, reducing recovery time, surgical risks, and hospital stays. Additionally, a growing emphasis on women’s reproductive health and the increasing availability of non-invasive diagnostic methods, such as ultrasound and MRI, are contributing to early detection and treatment planning. With the rising trend toward patient-centric care, healthcare providers are prioritizing myomectomy as a safer and more effective alternative to traditional surgical procedures.How Are Technological Advancements Transforming Myomectomy Procedures?
The evolution of surgical technology has significantly enhanced the efficiency and safety of myomectomy procedures, making them more accessible to a larger patient population. The introduction of robotic-assisted surgery has revolutionized myomectomy by offering superior precision, minimal blood loss, and faster recovery times compared to conventional open surgery. Innovations in laparoscopic instruments and energy-based surgical devices, such as harmonic scalpels and radiofrequency ablation, have further improved the accuracy and success rates of fibroid removal. Additionally, the integration of artificial intelligence (AI) and real-time imaging systems is enabling surgeons to perform highly precise procedures with enhanced visualization and intraoperative decision-making capabilities. The shift toward outpatient and same-day surgery centers is also facilitating greater adoption of minimally invasive myomectomy, reducing healthcare costs and increasing convenience for patients. As advancements in surgical robotics, AI-assisted diagnostics, and personalized treatment planning continue to emerge, the myomectomy market is poised for substantial growth, offering patients safer and more effective treatment options.What Are the Emerging Trends in Myomectomy and Fibroid Management?
The myomectomy market is being shaped by evolving treatment approaches and patient preferences, driving new trends in fibroid management. One notable trend is the increasing demand for uterus-sparing procedures, reflecting a shift in women’s healthcare priorities toward fertility preservation and improved quality of life. The adoption of integrative and multimodal treatment strategies, including hormonal therapy and non-surgical interventions like high-intensity focused ultrasound (HIFU), is also gaining traction as complementary approaches to myomectomy. Additionally, advancements in pharmacological treatments, such as GnRH antagonists and selective progesterone receptor modulators (SPRMs), are helping shrink fibroids preoperatively, making surgery less invasive and reducing potential complications. The rising role of telemedicine and digital health platforms is further enhancing patient engagement, allowing for remote consultations, pre-surgical assessments, and post-operative care management. Furthermore, an increasing focus on health equity and awareness campaigns is leading to better access to fibroid treatment options for underserved populations. As patient education and non-invasive alternatives continue to expand, myomectomy is expected to remain a cornerstone in fibroid treatment strategies.What Factors Are Driving Market Growth?
The growth in the myomectomy market is driven by several factors, including rising fibroid incidence, advancements in minimally invasive surgical techniques, and increasing patient awareness about fertility-preserving treatment options. The expanding prevalence of uterine fibroids among women of reproductive age has heightened the demand for effective and uterus-sparing interventions. Technological innovations, such as robotic-assisted surgery, AI-powered diagnostics, and improved surgical instrumentation, are enabling safer and more precise procedures, contributing to market expansion. The growing number of ambulatory surgical centers (ASCs) offering outpatient myomectomy services is also making the procedure more accessible and cost-effective for patients. Additionally, supportive healthcare policies and increasing insurance coverage for fibroid treatments are encouraging more women to opt for myomectomy over hysterectomy. Pharmaceutical advancements, particularly in preoperative fibroid management, are further enhancing surgical outcomes and expanding treatment possibilities. As the focus on women’s health and reproductive care intensifies, the myomectomy market is expected to witness continued growth, solidifying its role as a leading option for fibroid management worldwide.Report Scope
The report analyzes the Myomectomy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product Type (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer, Other Product Types); Procedure Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Laparoscopic Power Morcellators segment, which is expected to reach US$464.9 Million by 2030 with a CAGR of a 9.1%. The Harmonic Scalpel segment is also set to grow at 8.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $212.3 Million in 2024, and China, forecasted to grow at an impressive 12.6% CAGR to reach $266.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Myomectomy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Myomectomy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Myomectomy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Advanced Surgical Concepts, B. Braun SE, Blue Endo, CONMED Corporation, Cook Medical Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 43 Featured):
- Advanced Surgical Concepts
- B. Braun SE
- Blue Endo
- CONMED Corporation
- Cook Medical Inc.
- CooperSurgical Inc.
- Ethicon, Inc. (Johnson & Johnson)
- Gynesonics
- Hologic Inc.
- INSIGHTEC Ltd.
- Intuitive Surgical Inc.
- KARL STORZ SE & Co. KG
- LiNA Medical ApS
- Lumenis Ltd.
- Medtronic plc
- Minerva Surgical Inc.
- Olympus Corporation
- Philips Healthcare
- Richard Wolf GmbH
- Stryker Corporation
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Surgical Concepts
- B. Braun SE
- Blue Endo
- CONMED Corporation
- Cook Medical Inc.
- CooperSurgical Inc.
- Ethicon, Inc. (Johnson & Johnson)
- Gynesonics
- Hologic Inc.
- INSIGHTEC Ltd.
- Intuitive Surgical Inc.
- KARL STORZ SE & Co. KG
- LiNA Medical ApS
- Lumenis Ltd.
- Medtronic plc
- Minerva Surgical Inc.
- Olympus Corporation
- Philips Healthcare
- Richard Wolf GmbH
- Stryker Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 376 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 779.3 Million |
Forecasted Market Value ( USD | $ 1200 Million |
Compound Annual Growth Rate | 8.0% |
Regions Covered | Global |